Today's Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC
Published Date: 16 Sep 2026

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Read More
Could Burnout Become the Employer’s Responsibility?
Published Date: 16 Sep 2026

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

Read More
High CLL Remission Seen With First-Line Triplet Regimen
Published Date: 16 Sep 2026

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

Read More
FET-PET Agent Approved for Glioma Imaging
Published Date: 16 Sep 2026

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Read More

Latest News


Latest News

News All Time


Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More cancer cases in areas where incarceration rates are high: Study

2.

Dasatinib Fails to Improve Outcomes in CBF-AML

3.

Housing aid linked to lower medical financial hardship among US renters with cancer

4.

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

5.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors



© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot